Bayer (BAYN.DE) shares are down around 7% early this week after the company received a Roundup verdict and was ordered to pay a $2.1 billion penalty. The company has already paid out a total of $10 billion to settle disputed claims, and more than 66,000 more cases are still pending.
A jury in Georgia, South Carolina, US, has ordered Monsanto parent company Bayer to pay damages to a man who claims the company’s Roundup weedkiller caused him cancer. “Bayer will likely be able to significantly reduce the punitive damages on appeal, as well as appeal the jury’s findings, although this will take some time,” JP Morgan analysts added.
The company’s shares are once again negating gains on the 200-day EMA (golden line on the chart) and extending a long-term downtrend.
Source: xStation
Oracle shares fall 6% amid fears of financial troubles 🔎
Lennar dips 4.6% after publishing quarterly earnings💡
DE40: Many informations, few movements
From Euphoria to Correction: CoreWeave and the Future of AI Infrastructure
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
